Bispecific antibody · Immune activation, directed at CD3 (CD3E) and CD38 · developed by Xencor
AMG 424 is a humanized bispecific antibody that binds CD3 on T cells and CD38 on tumor cells. Cross-linking the two may trigger a cytotoxic T-lymphocyte response against CD38-expressing cells. It is studied in relapsed or refractory multiple myeloma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03445663 | Phase 1 | Relapsed/ Refractory Multiple Myeloma | Terminated | XNCR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Relapsed/ Refractory Multiple Myeloma
Updated Nov 1, 2026. Something wrong or missing? Report it on the XNCR page.
See XNCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
XNCR catalysts and pipeline →